Why Is ZENAS BIOPHARMA INC Equity (ZBIO) Stock Up Today?

Zenas BioPharma Inc. (ZBIO) shares rose 7.19% to $28.91 in morning trading on October 1, 2026, driven by a series of analyst upgrades and upcoming data presentations. The stock opened with a 2.7% gap up and reached a session high of $28.99 before settling near that level. Recent analyst activity and a strong intraday performance highlight growing investor interest in the biopharmaceutical company.

What Happened

Citi raised its price target for Zenas BioPharma to $48 from $41, reinforcing a positive outlook for the stock. H.C. Wainwright also reiterated its Buy rating ahead of the upcoming PDUFA date. These developments came alongside a presentation from Zenas BioPharma on its prelaunch strategy for obexelimab in treating IgG4-related disease. The company is also set to present new data from its Phase 3 INDIGO trial at the 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026. These events have contributed to a broader sense of optimism among investors.

What The Data Shows

Zenas BioPharma opened at $27.70 and traded as low as $26.55 before rebounding. The stock reached a session high of $28.99 and closed the morning at $28.86. The volume of 0.2 million shares was 0.3 times the 3-month daily average, suggesting moderate but growing participation. The stock printed one fresh 52-week high on October 1 and remains within its 52-week range of $13.50 to $44.60. Despite a recent rise, the company remains unprofitable with a TTM EPS of -9.05 and revenue down 93.3% year-to-date.

What To Watch

Investors should monitor the PDUFA date for regulatory updates on obexelimab and the data presentations in late 2026. Coverage breadth is also worth tracking, as recent analyst activity has increased.